MedTrace Logo

Treatment of Chronic Wound Biofilms

NCT01646502 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2014-10-07

No results posted yet for this study

Summary

Chronic wounds cause significant morbidity and cost our healthcare system millions of dollars each year.Their healing is slowed by biofilms, communities of bacteria surrounded by a protective layer that stops the immune system and antibiotics from getting close enough to kill them. The investigators will develop a new strategy to destroy biofilms using a protein made from bacteria that live on our skin.The Staphylococcus epidermidis Esp protein will be used to destroy Staphylococcus aureus biofilms, the most common bacterium in chronic wounds. The investigators hypothesize that the use of the Esp protein will breakdown S. aureus biofilms, decrease bacterial colonization of chronic wounds and improve healing times.

Conditions

  • Chronic Wound
  • Venous Insufficiency
  • Biofilms

Interventions

BIOLOGICAL

Esp protein

OTHER

Standard wound care

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Brian Kunimoto, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01646502 on ClinicalTrials.gov